MRPL23 (mitochondrial ribosomal protein L23) is a structural component of the mitochondrial large ribosomal subunit involved in mitochondrial translation 1. While its primary canonical function relates to protein synthesis in mitochondria, MRPL23 has emerged as a clinically significant gene in multiple cancer contexts. In prostate cancer, MRPL23 expression is elevated in tumor tissues compared to normal epithelium, with highest levels in lymph node metastases, and high expression independently predicts shorter overall survival 2. Similarly, in clear cell renal cell carcinoma, MRPL23 expression status combined with MATR3 predicts patient survival better than either marker alone 3. MRPL23 is also associated with Alzheimer's disease pathogenesis, identified as a key gene linked to M1 macrophage infiltration in affected prefrontal cortex tissue 1, and differentially expressed in neuropathic pain conditions 4. Additionally, the lncRNA MRPL23-AS1 (an antisense transcript) promotes metastasis in adenoid cystic carcinoma by suppressing E-cadherin through EZH2 interaction and inhibiting anoikis-mediated apoptosis 56, and drives osteosarcoma progression via the miR-30b/MYH9 axis 7. These findings suggest MRPL23 represents both a prognostic biomarker and potential therapeutic target across multiple malignancies.